Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Chow

Showing results (721-730 of 736) with videos related to

Pageof 74
Sort By:
BMC Medical Education|July 2, 2025
Achievement emotions in healthcare education: understanding the application of achievement emotions questionnaireFraide A Ganotice, Xiaoai Shen, John Ian Wilzon Tolentino Dizon, et al.
Nature Biotechnology|April 28, 2022
Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variantsJason Z Zhang, Hsien-Wei Yeh, Alexandra C Walls, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Nature Communications|July 11, 2024
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
World Neurosurgery|February 8, 2021
Surgical or Endovascular Management of Middle Cerebral Artery Aneurysms: A Randomized ComparisonTim E Darsaut, Michael B Keough, Abdelaziz Sagga, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Nature Communications|September 13, 2023
De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8Anindya Roy, Lei Shi, Ashley Chang, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
<i>De novo</i> design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8Anindya Roy, Lei Shi, Ashley Chang, et al.
Pageof 74

Showing results (721-730 of 736) with videos related to

Sort By:
Pageof 74
BMC Medical Education|July 2, 2025
Achievement emotions in healthcare education: understanding the application of achievement emotions questionnaireFraide A Ganotice, Xiaoai Shen, John Ian Wilzon Tolentino Dizon, et al.
Nature Biotechnology|April 28, 2022
Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variantsJason Z Zhang, Hsien-Wei Yeh, Alexandra C Walls, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerHossein Borghaei, Scott Gettinger, Everett E Vokes, et al.
Nature Communications|July 11, 2024
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
World Neurosurgery|February 8, 2021
Surgical or Endovascular Management of Middle Cerebral Artery Aneurysms: A Randomized ComparisonTim E Darsaut, Michael B Keough, Abdelaziz Sagga, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Nature Communications|September 13, 2023
De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8Anindya Roy, Lei Shi, Ashley Chang, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
<i>De novo</i> design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8Anindya Roy, Lei Shi, Ashley Chang, et al.
Pageof 74